Irvine-based Biolase Inc. (Nasdaq: BIOL) on Aug. 8 named Todd Norbe president and chief executive.
Newport Beach’s Carrick Capital Partners LLC bought a majority stake in Discovery Health Partners, a payments company in the health industry. Terms weren’t disclosed.
Ontario-based Prime Healthcare Services Inc. and its chief executive have agreed to pay $65 million to settle federal allegations of Medicare overbilling at 14 California Hospitals, including four in Orange County, the U.S. Attorney’s Office said Aug. 3.
Masimo Corp. (Nasdaq: MASI) reported revenue of $211.6 million, including royalty, with product revenue for the second quarter totaling $202 million, up 12.4% compared to the same quarter a year ago.
Irvine-based Quality Systems Inc. (Nasdaq: QSII) reported $133.2 million in revenue for its latest quarterly results, a 1.7% year-over-year increase.
Shares of Irvine’s CorVel Corp. surged 4.8% to $57.35 in after hours trading Tuesday after the insurance managed service provider reported first-quarter earnings rose 35% to 62 cents a share. Shares gave back those overnight gains in midday trading Wednesday.
Evolus Inc. (Nasdaq: EOLS) priced an additional public offering of 4 million shares of common stock at $20 each. The offering consists of 3 million shares offered by the medical aesthetics company and a million shares offered by a selling stockholder.
Irvine-based Urovant Sciences Inc. is seeking $150 million via the public markets to extend clinical trials of therapies to treat urologic conditions.
The David and Molly Pyott Foundation gave a $1.7 million gift to Easterseals Southern California (ESSC).
Evolus Inc. named Michael Jafar chief marketing officer, a new position, and its second recent hire from the executive ranks of Allergan plc.
PeproMene Bio Inc. raised $40.2 million from 17 investors in a Series B funding round, a June 11 Securities and Exchange Commission filing said.
San Clemente-based ReShape Lifesciences Inc. (Nasdaq: RSLS) raised nearly $1.5 million from several institutional investors for the purchase of 374,572 shares of its common stock at $3.92 per share, according to filings with the Securities and Exchange Commission.
Richard Gannotta was named chief executive of UCI Health, the clinical, medical education and research arm of the University of California-Irvine.